Omni Bio Pharmaceutical, Inc.
5350 South Roslyn
Suite 400
Greenwood Village,
CO 80111
United States - Map
Phone: 303-867-3416
Web Site: http://www.omnibiopharma.com
| Index Membership: | N/A | | Sector: | N/A | | Industry: | N/A | | Full Time Employees: | N/A |
|
| Omni Bio Pharmaceutical, Inc., a development stage biopharmaceutical company, focuses on the acquisition, licensing, and development of existing novel therapies. It is developing a portfolio of therapeutics targeting bacterial and viral diseases, biohazards, diabetes, and transplant rejection. The companys products include Alpha 1 Antitrypsin for treating organ transplantation, including islet transplantation for the treatment of diabetes and bacterial infections, such as bacterial pneumonia, tuberculosis, and anthrax. Omni Bio Pharmaceutical also holds a patent for the treatment of viral infection comprising HIV, influenza, and the bird flu virus. It has a research and licensing agreement with the University of Colorado to further scientific study on a previously FDA-approved pharmaceutical's method of action on various forms of viral illness. The company is based in Greenwood Village, Colorado. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Charles Dinarello M.D., 66
Acting Chief Exec. Officer, Director and Member of Scientific Advisory Board |
N/A
| N/A | Mr. Robert Ogden , 48
Chief Financial Officer, Principal Accounting Officer, Sec. and Treasurer |
N/A
| N/A | Mr. Edward C. Larkin , 58
Chief Operating Officer and Exec. VP |
N/A
| N/A | Dr. Leland Shapiro ,
Scientific Consultant |
N/A
| N/A |
|
|
|
Dollar amounts are as of
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.67% Nasdaq 0.00%
Profile
